$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Seagen Inc’s Revenue by Segment, split across Collaboration and license agreement, Royalty, and Net product sales segments, reported quarterly from Q1 2016 onwards.
Seagen Inc’s Revenue by Segment
|Segment||2022 Q1||2022 Q4||2023 Q1||YoY Growth (2023 Q1)|
|Collaboration and license agreement revenues||15,193.0||49,470.0||20,902.0||38%|
|Net product sales||3,83,086.0||8,91,716.0||4,68,639.0||22%|
(All the values are in thousand dollar except percentage)
Seagen Inc has achieved outstanding overall growth when revenue from collaboration and licence agreements, net product sales, and royalty revenues are combined. Seagen Inc’s total revenue was $426,460,000 in the first quarter of 2022, rising to $1,038,450,000 in the fourth quarter of the same year. The pattern of increase continued in the first quarter of 2023, with total sales of $519,719,000. The 22% growth rate in the first quarter of 2023 reflects Seagen Inc’s overall strong performance in diversifying its revenue streams and extending its market position.
Cooperation and Licence Agreement Revenues:
Seagen Inc’s cooperation and licence agreement revenues have increased significantly in recent quarters. Revenue stood at $15,193,000 in the first quarter of 2022, increased to $49,470,000 in the fourth quarter of the same year, and then settled at $20,902,000 in the first quarter of 2023. This translates to a 38% growth rate in the first quarter of 2023. Seagen Inc’s effective partnerships and licencing agreements are highlighted by the increased trend in collaboration and licence agreement revenues, indicating its capacity to develop productive collaborations within the biotechnology industry.
Net Product Sales:
Over the quarters, Seagen Inc’s net product sales have continuously increased. Net product sales were $383,086,000 in the first quarter of 2022. It had expanded greatly to $891,716,000 by the fourth quarter of 2022, and it had further increased to $468,639,000 in the first quarter of 2023. Seagen Inc’s efficient marketing techniques and successful commercialization of its revolutionary cancer medicines resulted in a 22% growth rate in the first quarter of 2023. This expansion indicates the company’s capacity to address the demands of patients and healthcare providers as well as the high demand for Seagen Inc’s products.
The royalty revenues of Seagen Inc have been steadily increasing. Royalty revenues were $28,181,000 in the first quarter of 2022, climbed to $97,264,000 in the fourth quarter of the same year, and then settled at $30,178,000 in the first quarter of 2023. The 7% growth rate in the first quarter of 2023 demonstrates Seagen Inc’s potential to create consistent royalties income. These revenues are frequently earned via licencing agreements, demonstrating Seagen Inc’s intellectual property and product portfolio’s success.
Seagen Inc. is a major biotechnology firm focused on the discovery of novel cancer medicines. Seagen seeks to deliver better therapeutic alternatives for people with difficult conditions by focusing heavily on research and development. The company’s competence is in collaboration and licencing agreements, net product sales, and royalty revenues, all of which have experienced rapid growth. Seagen’s dedication to cancer research is shown in its successful partnerships and commercialization methods. Seagen Inc. continues to make important contributions to the area of biotechnology and enhance the lives of patients worldwide by leveraging its intellectual property and product portfolio.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.